Overview
I am a surgeon with interest in immune management of transplant recipients. I am particularly interested in therapies that influence T cell costimulation pathways and adjuvant therapies that facilitate costimulation blockade to prevent the rejection of transplanted organs without undue suppression of protective immunity. I am also interested in understanding how injury, such as that occurring during trauma or in elective surgery, influences immune responses and subsequent healing following injury.
Current Appointments & Affiliations
David C. Sabiston, Jr. Distinguished Professor of Surgery
·
2015 - Present
Surgery, Abdominal Transplant Surgery,
Surgery
Professor of Surgery
·
2014 - Present
Surgery, Abdominal Transplant Surgery,
Surgery
Chair of Surgery
·
2014 - Present
Surgery,
Clinical Science Departments
Professor in Pediatrics
·
2014 - Present
Pediatrics,
Clinical Science Departments
Professor in Integrative Immunobiology
·
2014 - Present
Integrative Immunobiology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2015 - Present
Duke Cancer Institute,
Institutes and Centers
Core Faculty in Innovation & Entrepreneurship
·
2021 - Present
Duke Innovation & Entrepreneurship,
University Initiatives & Academic Support Units
Recent Publications
Development of a natural language processing algorithm to extract social determinants of health from clinician notes.
Journal Article Am J Transplant · March 6, 2025 Disparities in access to the organ transplant waitlist are well-documented, but research into modifiable factors has been limited due to lack of access to organized pre-waitlisting data. This study aimed to develop a natural language processing algorithm t ... Full text Link to item CiteConsortium for the Holistic Assessment of Risk in Transplant: Harmonizing Data for Research, Transparency, and Equity.
Journal Article Ann Surg · March 1, 2025 Full text Link to item CiteImmunomodulation of T cell-mediated alloimmunity by proximity to endothelial cells under the mammalian target of rapamycin blockade.
Journal Article Am J Transplant · February 2025 Endothelial cells (ECs) are an initial barrier between vascularized organ allografts and the host immune system and are thus well positioned to initiate and influence alloimmune rejection. The mammalian target of rapamycin inhibitor rapamycin is known to i ... Full text Link to item CiteRecent Grants
Stimulating Access to Research in Residency (StARR) - NIAID
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2018 - 2029Advanced Immunobiology Traning Program for Surgeons
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2029Tolerance to Allogeneic Hearts via Implantation of Cultured Donor Thymus
ResearchAdvisor · Awarded by National Institutes of Health · 2025 - 2028View All Grants
Education, Training & Certifications
Duke University ·
1992
Ph.D.
Duke University, School of Medicine ·
1987
M.D.
Old Dominion University ·
1983
B.S.